After receiving the local ethics committee approval, between October
2019 and July 2020, in this prospective and comparative trial, a total
of 120 consecutive patients with BPH induced LUTS refractory to medical
treatment or developing complications secondary to prostatic obstruction
were included and divided into two groups based on the power of the
device used namely Group 1 (50 watt) and group 2 (100 watt) groups. The
patients were assigned respective numbers according to the hospital
admission time, and these numbers were then classified as odd numbers in
group 1 and even numbers in group 2. Exclusion criteria were
neurological disorder (e.g.Parkinson’s disease, cerebral ischemic
event), active urinary infection, active hematuria, prostate cancer and
previous urethral or prostatic surgery.
Following medical history and digital rectal examination, urine culture,
serum prostate specific antigen (PSA, ng/ml), suprapubic
ultrasound-determined prostate volume (ml), American Society of
Anesthesiologists (ASA) scores, International Prostate Symptom Scores
(IPSS), maximum flow rates (Q max), postvoiding residual volumes (PVR),
and Quality of Life (QoL) index values were all assessed and recorded
prior to the procedure. Transrectal prostate biopsy was performed if
indicated and biopsy negative patients were operated at least 4 weeks
later.
Patients receiving coumadin stopped the medication 5 days before HoLEP
and were bridged with low molecular weight heparins during the
perioperative period. New oral anticoagulants (such as dabigatran,
rivaroxaban, apixaban, and edoxaban) were discontinued 48-72 h before
surgery. Patients receiving acetylsalicylic acid and platelet
aggregation inhibitors (such as clopidogrel, ticagrelor, and prasugrel)
were operated under acetylsalicylic acid
treatment.Antithrombotic treatment
was resumed as soon as bleeding control was achieved. All preoperative
baseline characteristics were recorded.